Fasoracetam - Nobias Therapeutics
Alternative Names: Fasoracetam monohydrate- Nobias Therapeutics; NB-001 - Nobias TherapeuticsLatest Information Update: 17 Oct 2023
At a glance
- Originator Nobias Therapeutics
- Class Antiepileptic drugs; Neuroprotectants; Nootropics; Piperidines; Small molecules
- Mechanism of Action Cholinergic receptor agonists; GABA B receptor antagonists; Metabotropic glutamate receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II DiGeorge syndrome
Most Recent Events
- 09 Jun 2023 Nobias Therapeutics completes a phase II clinical trial in DiGeorge syndrome (In children, In adolescents) in USA and Canada (PO) (NCT05290493)
- 10 Feb 2022 Phase-II clinical trials in DiGeorge syndrome (In children, In adolescents) in Canada (PO) (NCT05290493)
- 10 Feb 2022 Phase-II clinical trials in DiGeorge syndrome (In children, In adolescents) in USA (PO) (NCT05290493)